Sharei Armon 4

What Happened

• Sharei Armon, a director of Genenta Science S.p.A. (GNTA), received a grant of 20,000 derivative shares (reported at $0.00) on March 30, 2026. The Form 4 classifies this as an award/acquisition (code A) and reports no cash paid for the grant.

Key Details

• Transaction date: 2026-03-30 (Form 4 filed 2026-04-01).
• Transaction type: Grant / award of 20,000 derivative shares (reported price $0.00; reported value $0).
• Vesting: Stock options vest in equal monthly installments over one year beginning March 30, 2026 (footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt — see the full Form 4 for total beneficial ownership.
• Timeliness: Filing appears timely (filed two days after the transaction); no late-filing flag noted.
• No 10b5-1 plan, tax withholding, or immediate sale/exercise was disclosed in the provided data.

Context

• This was a compensation award (stock options/derivative grant) for a director, not an open-market purchase or sale. The options vest monthly over 12 months and would only produce equity if and when exercised according to the company’s terms. Such grants are common for directors and, unlike outright purchases, do not necessarily signal a direct trading sentiment.